CEFT Pool (15nmol; >70%)

Product Code: PM-CEFT-1

Positive Control Pool of 27 peptides selected from defined HLA class I and II-restricted T-cell epitopes for T cell assays (e.g. ELISPOT). Amount: 1 vial containing 15 nmol (appr. 25µg) per peptidePurity: >70% (HPLC-MS)Delivery Format: Freeze dried in amber type glass vialApplication(s): T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune responseIndication(s)/Topic(s): ControlDelivery Time: 2-5 days

PepMixes™ Peptide PoolsThe use of complete protein-spanning mixtures of overlapping peptides (PepMix™) is extremely efficient for immunostimulation of T-lymphocytes and diagnostic applications. In order to establish reliable and validated T-cell assays such as ELISPOT, appropriate positive and negative controls are essential. Selection of such controls helps to confirm proper functionality of the assay as well as viability of the cells used. In addition, high quality controls are most important to establish standardized assay protocols in clinical setups. Compared to commonly used controls like phytohemagglutinin (PHA) and concanavalin A (ConA) that stimulate T-cells as well as other cell types or full length antigens, synthetic peptide pools offer the advantage of a high batch-to-batch reproducibility, applicability of reliable chemical and biochemical QC/QA measures and shelf stability when stored as freeze dried aliquots.

Benefits of PepMix™- Equivalent or better stimulation of CD4⁺ and CD8⁺ T-cell responses compared to whole protein antigens- Simultaneous detection of CD4⁺ and CD8⁺ responses in a single sample - Improved responses in stored blood and PBM cells compared to whole protein antigens- More reliable as control than phytohemagglutinin (PHA) and concanavalin A (ConA) - High-batch-to-batch reproducibility- Reliable chemical and biochemical quality control and quality assurance for peptide synthesis and peptide pool generation- Prolonged shelf stability when stored freeze dried

CEFT Pool (15nmol; >70%)

Selected References \"Standardization of Cryopreserved Peripheral Blood Mononuclear Cells Through a Resting Process for Clinical Immunomonitoring--Development of an Algorithm\" Wang et al., Cytometry A. (2015) - PMID: 26848928 \"Dichotomous Effects of Latent CMV Infection on the Phenotype and Functional Properties of CD8+ T-cells and NK-cells\" Bigley et al., Cellular Immunology (2015) - PMID: n.a \"K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo\" Caruana et al., Clin Cancer Res. (2015) - PMID: 25691731 \"Self-adjuvanted mRNA Vaccination in Advanced Prostate Cancer Patients: a First-in-Man Phase I/IIa Study\" Kübler et al., J Immunother Cancer. (2015) - PMID: 26082837 \"Guidelines For the Automated Evaluation of Elispot Assays\" Janetzki et al., Nature Protocols (2015) - PMID: 26110715 \"Profiling T Cell Activation Using Single-Molecule Fluorescence In Situ Hybridization and Flow Cytometry\" Bushkin et al., J. Immunol. (2015) - PMID: 25505292

Application Notes\"Developing Multi-HIV Antigen Specific T-Cells as a Component of a Cure Strategy\"Lam et al. (2015) Full text\"Peptide-stimulated Expansion of Virus-specific T cells For Preventative Treatment After Allogeneic Stem Cell Transplantation\"Gary et al. (2015) Full text

CEFT Pool (15nmol; >70%)